Last reviewed · How we verify
EDETATE CALCIUM DISODIUM ANHYDROUS
At a glance
| Generic name | EDETATE CALCIUM DISODIUM ANHYDROUS |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
Common side effects
Key clinical trials
- Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) (PHASE2)
- Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids (PHASE1)
- Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms (EARLY_PHASE1)
- Effect of Intranasal Corticosteroids on Pulmonary Symptoms in Asthmatics With Nasal Congestion (NA)
- Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EDETATE CALCIUM DISODIUM ANHYDROUS CI brief — competitive landscape report
- EDETATE CALCIUM DISODIUM ANHYDROUS updates RSS · CI watch RSS